Loading organizations...
§ Private Profile · Barcelona, Catalonia, Spain
Clinical-stage biotechnology company developing therapeutic vaccines and immunotherapies for HIV infection, focused on a functional cure.
Aelix Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain, that discovers and develops therapeutic vaccines and immunotherapies targeting HIV infection. The organization leverages clinical data from over 1,000 HIV-infected patients to develop its lead candidate, the HTI immunogen, which aims to elicit targeted T-cell immune responses for a potential functional cure. Operating with a lean team of approximately six core employees, the enterprise secured €11.5 million in Series A funding to advance its early-stage clinical trials and product development. The clinical pipeline and research initiatives are supported by prominent venture capital investors and strategic corporate partners, including Ysios Capital, Johnson & Johnson Innovation, Caixa Capital Risc, and Gilead Sciences. Aelix Therapeutics was founded in 2015 as a spin-off from the HIVACAT project by Jordi Naval, Christian Brander, Bonaventura Clotet, and Josep Maria Gatell.
Aelix Therapeutics has raised $14.7M across 2 funding rounds.
Aelix Therapeutics has raised $14.7M in total across 2 funding rounds.
Aelix Therapeutics has raised $14.7M in total across 2 funding rounds.
Aelix Therapeutics's investors include Caixa Capital Risc, CDTI, Ysios Capital, Karen Wagner, José Antonio Mesa, Jeanne Bolger.
Aelix Therapeutics has raised $14.7M across 2 funding rounds. Most recently, it raised $2.2M Other Equity in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 16, 2021 | $2.2M Venture Round | — | Caixa Capital Risc, Cdti, Ysios Capital | Announced |
| Jan 11, 2016 | $12.5M Series A | Karen Wagner | José Antonio Mesa, Jeanne Bolger | Announced |